Eli Lilly and Company

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Stanford University School of Medicine, Technology, Inflammation, Bayer, LinkedIn, Sofinnova, Industry, Protein engineering, Hematology, Disease, Merck, Pathology, CD8, Patient, ITI, Investment, Lead, Merck & Co., Institutional Venture Partners, Company, Eli Lilly and Company, CEO, Board, Stanford Institutes of Medicine Summer Research Program, Structural biology, Therapy, Immune system, Autoimmunity, SAB, Transplant, Doctor of Philosophy, Howard Hughes Medical Institute, Board of directors, Pharmaceutical industry, Vaccine, Management

SEATTLE, Oct. 26, 2021 /PRNewswire/ -- Mozart Therapeutics, Inc., a new biopharmaceutical company targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announced a $55 Million Series A Financing led by seed and Series A investor ARCH Venture Partners along with Sofinnova Partners. Additional investors include Eli Lilly & Company, MRL Ventures Fund (the early-stage therapeutics-focused fund of Merck & Co., Inc.), Leaps by Bayer, Altitude Life Science Ventures, Alexandria Venture Investments. 

Key Points: 
  • The technology was licensed to Mozart to develop therapeutic candidates that target and modulate this network for the treatment of autoimmune and inflammatory disease.
  • "Mozart is doing something truly unique to change the treatment paradigm for patients with autoimmune and inflammatory diseases.
  • CD8 Treg Modulators are disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract early events in the autoimmune inflammatory cascade.
  • Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Stanford University School of Medicine, Technology, Inflammation, Bayer, LinkedIn, Sofinnova, Industry, Protein engineering, Hematology, Disease, Merck, Pathology, CD8, Patient, ITI, Investment, Lead, Merck & Co., Institutional Venture Partners, Company, Eli Lilly and Company, CEO, Board, Stanford Institutes of Medicine Summer Research Program, Structural biology, Therapy, Immune system, Autoimmunity, SAB, Transplant, Doctor of Philosophy, Howard Hughes Medical Institute, Board of directors, Pharmaceutical industry, Vaccine, Management

SEATTLE, Oct. 26, 2021 /PRNewswire/ -- Mozart Therapeutics, Inc., a new biopharmaceutical company targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announced a $55 Million Series A Financing led by seed and Series A investor ARCH Venture Partners along with Sofinnova Partners. Additional investors include Eli Lilly & Company, MRL Ventures Fund (the early-stage therapeutics-focused fund of Merck & Co., Inc.), Leaps by Bayer, Altitude Life Science Ventures, Alexandria Venture Investments. 

Key Points: 
  • The technology was licensed to Mozart to develop therapeutic candidates that target and modulate this network for the treatment of autoimmune and inflammatory disease.
  • "Mozart is doing something truly unique to change the treatment paradigm for patients with autoimmune and inflammatory diseases.
  • CD8 Treg Modulators are disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract early events in the autoimmune inflammatory cascade.
  • Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

Retrieved on: 
Tuesday, October 26, 2021
Rigel, Research, SAN, ASA, Cancer, Disease, Tablet, Fostamatinib, Waiha, Eastern Time Zone, NIH, Patient, FDA, Degenerative disease, Eli Lilly and Company, Imperial College London, RIP1, Adult, Daiichi Sankyo, Company, Webcast, COVID-19, Investor relations, IRAK, Nasdaq, AstraZeneca, SYK, Pharmaceutical industry

(Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021.

Key Points: 
  • (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021.
  • Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.
  • In addition, Rigel has product candidates in development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
  • 1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, October 26, 2021
KOL, Eli Lilly and Company, Teaching hospital, Atopic dermatitis, MD, ASLN, Research, MAD, Ferda Mravenec, Icahn School of Medicine at Mount Sinai, University, Master of Science, Anacor, Disease, CA, Eczema Area and Severity Index, Skin, Patient, EASI, DHODH, Secondary research, Intention, ADSS, Company, Crisaborole, University of California, CEO, ADS, AD, Inflammatory bowel disease, Coronavirus Scientific Advisory Board (Turkey), Nasdaq, GLOBE, Mount Sinai, SAB, Bachelor of Medical Sciences, Doctor of Philosophy, Associate, Department, ITT, Pharmaceutical industry, Medical device, Lithium

MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.

Key Points: 
  • MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.
  • Research and development expenses were US$5.3 million in the third quarter of 2021 compared to US$2.2 million in the third quarter of 2020.
  • General and administrative expenses were US$2.8 million in the third quarter of 2021 compared to US$1.3 million in the third quarter of 2020.
  • Net loss for the third quarter of 2021 was US$8.6 million compared to a net loss of US$3.5 million for the third quarter of 2020.

AC Immune to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Monday, October 25, 2021
AU, Neurodegeneration, NO, CH, Hoffmann-La Roche, NASDAQ, AC, GB, Genentech, Eli Lilly and Company, RU, Conference, Precision medicine, Company, CEO, Janssen Pharmaceuticals, GLOBE, JP, Pharmaceutical industry

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.
  • The fireside chat will be available on-demand for attendees during the virtual conference beginning on November 18, 2021.
  • A replay of the fireside chat will also be available on the Events Page of AC Immunes website following the conferences conclusion.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

Qynapse Further Strengthens its Executive Leadership Team with the Appointment of Adam Schwarz, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, October 21, 2021
Lists of diseases, Science, MRI, Book, New Zealand, Central nervous system disease, Research, Eli Lilly, Technology, University, Imaging, Electrical engineering, Drug development, CNS, PET, Electronic engineering, Eli Lilly and Company, Takeda Pharmaceutical Company, Intelligence, CSO, Company, Psychiatry, Institute, Central nervous system, GlaxoSmithKline, Bachelor of Science, Medical device, Management

BOSTON, Oct. 21, 2021 /PRNewswire/ -- Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, announced today the appointment of Adam J. Schwarz, Ph.D., as Chief Scientific Officer (CSO).

Key Points: 
  • BOSTON, Oct. 21, 2021 /PRNewswire/ -- Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, announced today the appointment of Adam J. Schwarz, Ph.D., as Chief Scientific Officer (CSO).
  • In his new role, Dr. Schwarz is responsible for envisioning and developing Qynapse's scientific research strategies and operations, and for expanding and communicating their product offering and scientific validation with the scientific and customer communities.
  • Dr. Schwarz has an active scientific profile and has authored over a hundred peer-reviewed articles, two books and several invited book chapters.
  • Qynapse is headquartered in France, in the United States and in Canada.

Cancer Immunotherapy Market - Global Forecast up to 2026: Focus on Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors, Immunomodulators - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 21, 2021
Health, Oncology, Merck & Co., Research, Diagnosis, Immunotherapy, Cancer, Monoclonal antibody, HDAC, Bristol Myers Squibb, Patient, Eli Lilly and Company, Pfizer, Novartis, Investment, Pressure, Company, CAGR, Awareness, Immune system, Neutralizing antibody, Multiple myeloma, AstraZeneca, Therapy, Bayer, Metastasis, Pet, Vaccine, Pharmaceutical industry

The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Cancer Immunotherapy Market is projected to grow at the rate of 9.7% CAGR by 2026.
  • Immunotherapy is a type of treatment to cure cancer that utilizes a few parts of a person's immune system to fight cancer.
  • With the considerable pressure of increasing cancer cases and the side effects of other therapies, cancer immunotherapy has exhibited tremendous potential over the past few years.

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

Retrieved on: 
Wednesday, October 20, 2021
Technology, Research, Cardiology, Software, Biotechnology, Health, Pharmaceutical, Other Science, Science, Janus, Eli Lilly and Company, Peptide, Sclerosis, Â, TCG, LinkedIn, SVB Leerink, G protein-coupled receptor, The Shouty Track, Ulcerative colitis, Lead, Qiming Venture Partners, CEO, BVF, Patient, Industry, Series, Conditional sentence, Computational chemistry, GPCR, Therapy, Pharmaceutical industry, Fine chemical

ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).

Key Points: 
  • ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).
  • Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
  • With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations.
  • Joining Dr. Stevens are:
    SVB Leerink acted as exclusive financial advisor for ShouTis Series B financing.

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

Retrieved on: 
Wednesday, October 20, 2021
Eli Lilly and Company, Biotechnology, Cancer, Seribantumab, University of Tennessee Health Science Center, Internal medicine, Private Securities Litigation Reform Act, COVID-19, Oncology, U.S. Securities and Exchange Commission, Growth, Vanderbilt University, Security (finance), Precision medicine, Goal, NRG1, Clinical research, Disease, Therapy, La Trobe Institute for Molecular Science, Doctor of Pharmacy, Neoplasm, Leadership, Nasdaq, Risk, Drug, Patient, Eli Lilly, University, ABIM, Forward-looking statement, Vanderbilt, Pharmacist, Company, Pharmaceutical industry, Medical imaging

"Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.

Key Points: 
  • "Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.
  • "Valerie has an extensive background in oncology and a deep understanding of precision medicine, and under her leadership, Elevation Oncology is well positioned for success.
  • Prior to joining Elevation Oncology, Dr. Jansen served as Executive Medical Director at Mersana Therapeutics, a clinical-stage biopharmaceutical company with a focus in oncology, where she led clinical development of antibody-drug conjugate therapies for patients living with cancer.
  • She completed residency in Internal Medicine and fellowship in Medical Oncology through the ABIM Physician-Scientist Research Pathway at Vanderbilt.

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Friday, October 15, 2021
Pulmonary hypertension, World Health Organization, Janssen Pharmaceuticals, Janssen, Disease, Annual report, Hypertensive emergency, Private Securities Litigation Reform Act, Medication, Risk, Research, Eli Lilly and Company, Connective tissue disease, Johnson & Johnson, Health Canada Sodium Working Group, Blood, Tadalafil, Gold, WHO, Medicine, Patient, Health Canada, Company, Blood pressure, Association, Behavior, Board, University of Ottawa Heart Institute, Table, Heart, PAH, Security (finance), Health, Board of directors, III, U.S. Securities and Exchange Commission, Metabolism, Pulmonary Hypertension Association, Tablet, Vaccine, Ventricular septal defect, Science, Degenerative disease, Environmental remediation, Pharmaceutical industry, Phosphorus

Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.

Key Points: 
  • Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.
  • OPSYNVIshould be used in patients who are currently treated concomitantly with stable doses of macitentan 10mg and tadalafil 40mg (20mg x 2) as separate tablets.
  • If left untreated, PH can lead to right ventricle failure, a serious type of heart failure.
  • As a combination therapy, OPSYNVI conveniently offers two therapies in one daily pill simplifying treatment for patients."